Business, energy, technology, markets and global industry news from Business News Today

Section 232 tariffs

PharmaDeviceNews Section 232 tariffs
Representative image illustrating Boehringer Ingelheim’s $10B U.S. expansion and participation in TrumpRx.gov, highlighting the intersection of pharmaceutical manufacturing, direct drug pricing, and U.S. government policy.
Pharma & Biotech

Why Boehringer’s $10bn U.S. investment and TrumpRx deal may reshape pharma cost dynamics

Boehringer Ingelheim’s $10B U.S. investment and TrumpRx.gov deal may redefine drug pricing and supply chains. Find out what this changes for pharma now.

Read More